April 21, 2015
Weill Cornell Medical College investigators, led by Drs. Mark A. Rubin, Sandra J. Shin and Juan Miguel Mosquera, tried to validate a previously reported molecular finding on triple negative breast cancer that many hoped would lead to targeted treatments for the aggressive disease. Instead, they discovered that the findings were limited to a single patient and could not be applied to further clinical work. This discovery, published April 15 in Nature, amends the earlier work and underscores the importance of independent study validation and careful assay development.
